Enerflex (TSE:EFX – Free Report) had its target price raised by BMO Capital Markets from C$11.00 to C$15.00 in a report ...

Equifax (EFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stock analysts at National Bank Financial boosted their FY2025 earnings per share estimates for Enerflex in a research report ...

On Friday, Equifax Inc (EFX) stock saw a decline, ending the day at $248.27 which represents a decrease of $-13.94 or -5.32% from the prior close of $262.21. The stock opened at $257.81 and touched a ...

RBC Capital analyst Keith Mackey maintained a Buy rating on Enerflex (EFX – Research Report) today and set a price target of $12.00. The ...

Fintel reports that on November 18, 2024, Citigroup initiated coverage of Akero Therapeutics (NasdaqGS:AKRO) with a Buy ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three ...

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the ...

The study revealed that after 96 weeks of EFX treatment, over 40% of participants exhibited regression of liver fibrosis, a key indicator of MASH progression. This includes improvements in liver ...

SOUTH SAN FRANCISCO - Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company, announced significant clinical outcomes from its Phase 2b HARMONY study, evaluating the efficacy ...